Lantheus Holdings
Lantheus,headquartered inBillerica, Massachusetts,is a company in theradiopharmaceuticalsbusiness. It has strategic partnerships withBayer,Novartis,Regeneronas well asGE HealthcareandSiemens Healthineers.[1][2]
Lantheus Holding, which became a NASDAQ company in 2015, is the parent company of Lantheus Medical Imaging, Inc.[3](formerlyBMSMedical Imaging), Progenics Pharmaceuticals (acquired 2020),[4][5]Inc. and EXINI Diagnostics AB (est. 1999, acquired 2020).[6]Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden.[7][8][9]
References
[edit]- ^"Lantheus Holdings Inc Company Profile".GlobalData.Retrieved2024-05-06.
- ^"SEC Filing".Lantheus Holdings, Inc.2016-06-30.Retrieved2024-05-06.
- ^"Lantheus Medical Imaging Inc".Bloomberg.Retrieved2024-05-06.
develops, manufactures, and distributes diagnostic imaging products. The Company offers imaging agents that assist in the diagnosis of heart, vascular, and other diseases using nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies. Lantheus Medical Imaging markets its products worldwide.
- ^"Progenics Pharmaceuticals, Inc".LinkedIn.2018-09-01.Retrieved2024-05-06.
- ^Name, Drug (2022-04-13)."Technetium Tc 99m trofolastat".AdisInsight.Retrieved2024-05-06.
- ^"We empower patients for better healthcare with Artificial Intelligence".Exini Diagnostics AB.2024-02-06.Retrieved2024-05-06.
...established in 1999 to commercialize AI methods for automated analysis of diagnostic images developed by a research group at Lund University. As a certified medical device manufacturer, EXINI has developed automated analysis platforms for cardiac, brain and bone scans. The company has always been innovative, developing web-based systems in the early 2000s. EXINIs most widely distributed platform is used to calculate the automated Bone Scan Index, which quantifies the bone tumor burden in patients with metastatic prostate cancer.
- ^"Legal Notice".Lantheus.2023-03-01.Retrieved2024-05-06.
- ^"Lantheus Medical Imaging".Journal of Nuclear Medicine Technology.48(Supplement 1). Society of Nuclear Medicine: 87S–87S. 2020-06-01.ISSN0091-4916.PMID32605966.Retrieved2024-05-06.
- ^"XML 32 R8.htm IDEA: XBRL DOCUMENT".SEC.gov.2020-03-31.Retrieved2024-05-06.